Project Grant R01CA308125
Award Date 4/7/26
Completion Date 3/31/31
Dollars Obligated $696K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06519, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Yale University a $478,532 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This research initiative will investigate the biological and clinical significance of spatial immune heterogeneity in non-small cell lung cancer (NSCLC), with particular focus on characterizing how the spatial distribution of tumor-infiltrating lymphocytes (TILs) and tertiary...
- Federal Grant Award Summary Yale University received a $672,371 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2028. The grant funds development of ultra-sensitive mass spectrometry-based immunopeptidomics technology utilizing digital microfluidics to identify tumor-specific antigens (TSAs) for cancer immunotherapy applications. The project addresses current...
- Federal Grant Award Summary Yale University received a $610,637 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. The award supports the development and preclinical evaluation of a versatile drug delivery platform utilizing bioadhesive and non-adhesive biodegradable nanoparticles engineered for selective locoregional delivery of cytotoxic and immune conditioning agents to advanced...
- Federal Grant Award Summary Yale University received a $167,771 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded August 1, 2025, with completion targeted for July 31, 2027. The award supports research to elucidate the mechanisms of a novel human-specific immune checkpoint interaction between SIGLEC-7 and VSIG4 proteins. The research will utilize a humanized mouse platform (MISTRG6-A2) to develop in vivo models that investigate how...
- Federal Grant Award Summary Yale University received a $150,104 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, through August 31, 2028. The award supports research investigating the impact of aberrant 5-methylcytosine (m5c) messenger RNA (mRNA) modification on translation initiation and cancer development. The project will examine how dysregulated methyltransferase expression in cancer cells affects...
- Federal Grant Award Summary Yale University received a $147,486 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) awarded July 1, 2025, with a completion date of June 30, 2028. This research grant funds investigation into the role of glycosylated RNAs (glycoRNAs)—RNA molecules post-transcriptionally modified with sialylated-N glycans—in acute myeloid leukemia (AML). The project delivers scientific research outputs across three primary aims:...
- Federal Grant Award Summary Yale University received a $735,631 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective April 1, 2026, through March 31, 2031. The award funds basic immunological research investigating the origin, function, and biological properties of a novel population of CX3CR1+ neutrophils—specialized white blood cells distinct from canonical neutrophils. The research...
- Federal Project Grant Award Summary Yale University received a $192,564 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, through August 31, 2028. The award supports research focused on developing a novel dual-target PROTAC (Proteolysis Targeting Chimera)-based protein degrader to address therapy resistance in metastatic castration-resistant prostate cancer (MCRPC). The project leverages a newly developed...
- Federal Project Grant Award Summary Yale University received a $1.5 million Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 1, 2025, through August 31, 2028. The award funds the development of a systems immunopeptidomics framework designed to investigate the role of self-peptides in regulating T cell immune responses. The research integrates next-generation mass spectrometry,...
- Yale University received a $482,312 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 2, 2026, through March 31, 2031. The award funds research to develop a novel therapeutic approach for inactivating regulatory T (Treg) cells through targeted protein degradation as a strategy to overcome immunotherapy resistance in cancer patients. The research builds on preliminary findings demonstrating that degradation of...